MDxHealth Licensee Exact Sciences Confirms Use of Biomarker and Methylation Technology in its Advanced Colon Cancer Test

DURHAM, NC, and LIEGE, BELGIUM - January 10, 2011 - MDxHealth SA (NYSE Euronext:
MDXH),  a leading  molecular diagnostics  company in  the field  of personalized
cancer  treatment,  today  announced  that  Exact  Sciences  (Nasdaq:  EXAS) has
confirmed  that it  is using  an MDxHealth  methylation biomarker  together with
MDxHealth's  methylation specific  PCR (MSP)  platform in  Cologuard(TM), a non-
invasive  stool-based  DNA  colon  cancer  screening test. This confirmation has
triggered  a milestone payment to MDxHealth  from Exact Sciences. MDxHealth will
also  receive royalties on net sales once  the test is commercialized. Under the
terms of a licensing agreement announced in August 2010, Exact Sciences has been
evaluating  several MDxHealth  methylation biomarkers,  among other  markers, as
well as the MSP technology in studies with its stool-based colon cancer test.
 
In  October 2010, Exact Sciences presented positive  data from a study involving
samples from 1,100 patients demonstrating the ability of Cologuard to detect 64
percent  of colorectal pre-cancers  and 85 percent of  colorectal cancers. Exact
Sciences  is now preparing to enroll  several thousand patients in a prospective
trial  to  obtain  approval  from  the  U.S. Food and Drug Administration. Trial
completion is expected in 2012 and the test, if approved, could be launched soon
after.
 
"Following  the promising Cologuard data presented in October, confirmation that
our  biomarker and MSP technology have  been incorporated is a significant event
for  MDxHealth  as  it  further  validates  our core capabilities," said Dr. Jan
Groen,  Chief Executive Officer of MDxHealth. "Exact Sciences has a unique focus
on colon cancer and is well positioned to ensure patients will benefit from this
important colon cancer screening test in the near term."
 
About MDxHealth
 
MDxHealth   is  a  leading  molecular  diagnostics  company  that  develops  and
commercializes  oncology-based  molecular  diagnostic  testing  for personalized
medicine.  The  company's  tests  are  based  on  proprietary  gene  methylation
technology  and assist  physicians with  the diagnosis  of cancer,  prognosis of
recurrence  risk, and  prediction of  response to  a specific therapy. MDxHealth
collaborates  with  leading  cancer  research  centers  such  as  Johns  Hopkins
University,  Duke University,  Lovelace Respiratory  Research Institute, Eastern
Virginia  Medical School, Cleveland Clinic,  Memorial Sloan Kettering, and major
European  academic medical centers.  The company has  a number of commercial and
collaborative   partnerships   with   LabCorp,   Merck  &  Co./Schering  Plough,
GlaxoSmithKline  Biologicals, Roche,  Merck Serono,  Qiagen, and  other industry
leaders.
 
MDxHealth to present today at Biotech Showcase in San Francisco
 
MDxHealth  will present at the Biotech  Showcase Conference in San Francisco, on
Monday, Jan.  10, 2011. Dr.  Jan  Groen,  chief  executive  officer, will make a
formal  presentation on the company at 2 p.m. Pacific time. The Biotech Showcase
runs  parallel to the 28th  Annual J.P. Morgan  Healthcare Conference, and takes
place at Parc 55 Wyndham San Francisco - Union Square.
 
MDxHealth is now on Twitter
 
Key topics and information linked to MDxHealth activities will be uploaded on
Twitter and available for reading to the MDxHealth followers. Tweets will be
generated on a regular basis.
 
In order to keep you updated on events and activities in the field of interest
of MDxHealth, we kindly invite you to be a follower of MDxHealth on Twitter. To
do so please follow the instructions below:
 
Go to www.twitter.com
 
Sign up and create your account.
 
You will get an e-mail where you have to confirm to have full access to twitter.
 
Go to www.twitter.com/mdxhealth and push the bottom " + Follow"
 
Now you should be a Follower of MDxHealth. Please join us in this new
experience.
 
For more information:
 
Dr. Jan Groen, CEO                           Hans Herklots
 
MDxHealth                                        Capricorn One
 
+32 4 364 20 70                                 +41 79 598 7149
 
This  press  release  contains  forward-looking  statements  and  estimates with
respect  to the  anticipated future  performance of  MDxHealth and the market in
which  it operates. Such  statements and estimates  are based on assumptions and
assessments  of known and unknown risks,  uncertainties and other factors, which
were  deemed  reasonable  but  may  not  prove  to be correct. Actual events are
difficult  to predict,  may depend  upon factors  that are  beyond the Company's
control,  and  may  turn  out  to  be  materially different. MDxHealth expressly
disclaims  any obligation to update any  such forward-looking statements in this
release  to reflect any  change in its  expectations with regard  thereto or any
change  in events,  conditions or  circumstances on  which any such statement is
based unless required by law or regulation
 
2011-01-10 Exact Sciences ENG: 
http://hugin.info/137314/R/1478172/414074.pdf
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: MdxHealth via Thomson Reuters ONE
 
[HUG#1478172]